Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Editas Medicine Inc (EDIT)
NASDAQ:EDIT
Holding EDIT?
Track your performance easily
EDIT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.90 - $11.69
Previous Close$2.9
Volume1.88M
Average Volume (3M)1.89M
Market Cap
$239.18M
Enterprise Value-$1.23M
Total Cash (Recent Filing)$279.11M
Total Debt (Recent Filing)$38.70M
Price to Earnings (P/E)―
Beta2.12
Next Earnings
Nov 06, 2024EPS Estimate
-$0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.36
Shares Outstanding82,476,436
10 Day Avg. Volume2,224,748
30 Day Avg. Volume1,893,964
Standard Deviation0.28
R-Squared0.14
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.24
Price to Sales (P/S)3.57
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.02
Enterprise Value/Gross Profit-0.02
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$10.33Price Target Upside254.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
Editas Medicine News
PremiumCompany Announcements
Editas Medicine Secures $57M Deal for Gene-Editing Technology
Bulls Say, Bears Say
Bulls Say
Clinical Trials And DataEditas will share updated data from the RUBY and EdiTHAL trials of its Cas12a-edited HSC product reni-cel in sickle cell disease and transfusion-dependent beta thalassemia at the European Hematology Association.
Financial StabilityEditas Medicine has a strong cash position, which is expected to provide financial stability into 2026.
Strategic PartnershipsThe partnership agreement with Genevant Sciences for LNP technology advances additional in vivo assets, potentially leading to significant milestone payments up to $238 million.
Bears Say
Commercialization ChallengesThe decision to out-license the reni-cel program reflects the crowded nature of the SCD space and the shift in focus towards in vivo gene editing.
Competitive PressureThe absence of an in vivo program in Editas' pipeline has been notable compared to primary competitors, which may indicate a competitive disadvantage.
Financial PerformanceThe early-stage nature of the in vivo pipeline has led to a reduction in the price target as additional data is awaited to validate the platform.
---
Ownership Overview
0.95% Insiders
16.70% Mutual Funds
0.62% Other Institutional Investors
67.76% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EDIT FAQ
What was Editas Medicine Inc’s price range in the past 12 months?
Editas Medicine Inc lowest stock price was $2.90 and its highest was $11.69 in the past 12 months.
What is Editas Medicine Inc’s market cap?
Currently, no data Available
When is Editas Medicine Inc’s upcoming earnings report date?
Editas Medicine Inc’s upcoming earnings report date is Nov 06, 2024 which is in 4 days.
How were Editas Medicine Inc’s earnings last quarter?
Editas Medicine Inc released its earnings results on Aug 07, 2024. The company reported -$0.82 earnings per share for the quarter, missing the consensus estimate of -$0.704 by -$0.116.
Is Editas Medicine Inc overvalued?
According to Wall Street analysts Editas Medicine Inc’s price is currently Undervalued.
Does Editas Medicine Inc pay dividends?
Editas Medicine Inc does not currently pay dividends.
What is Editas Medicine Inc’s EPS estimate?
Editas Medicine Inc’s EPS estimate is -$0.75.
How many shares outstanding does Editas Medicine Inc have?
Editas Medicine Inc has 82,476,430 shares outstanding.
What happened to Editas Medicine Inc’s price movement after its last earnings report?
Editas Medicine Inc reported an EPS of -$0.82 in its last earnings report, missing expectations of -$0.704. Following the earnings report the stock price went down -12.179%.
Which hedge fund is a major shareholder of Editas Medicine Inc?
Among the largest hedge funds holding Editas Medicine Inc’s share is Woodline Partners LP. It holds Editas Medicine Inc’s shares valued at 5M.
---
Editas Medicine Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.33 (254.98% Upside)
$10.33 (254.98% Upside)
Blogger Sentiment
Bullish
EDIT Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 132.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.58%
12-Months-Change
Fundamentals
Return on Equity
-61.23%
Trailing 12-Months
Asset Growth
-29.00%
Trailing 12-Months
Company Description
Editas Medicine Inc
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
---
EDIT Earnings Call
Q2 2024
0:00 / 0:00
---
EDIT Stock 12 Month Forecast
Average Price Target
$10.33
▲(254.98% Upside)
Technical Analysis
Crispr Therapeutics AG
―
Intellia Therapeutics
―
Beam Therapeutics
―
Sangamo Biosciences
―
Best Analysts Covering EDIT
1 Year
1 Year Success Rate
5/13 ratings generated profit
1 Year Average Return
-3.55%
reiterated a buy rating 3 months ago
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of -3.55% per trade.
---